Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27029040 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL3699371 | 0.98 | ALDH1A1 (0.62) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL8371513 | 0.91 | ALDH1A1 (0.59) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL3683901 | 0.89 | ALDH1A1 (0.60) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL3681798 | 0.88 | ALDH1A1 (0.63) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL18477951 | 0.87 | ALDH1A1 (0.66) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL3211688 | 0.86 | ALDH1A1 (0.56) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL7992010 | 0.86 | ALDH1A1 (0.56) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL3210160 | 0.86 | ALDH1A1 (0.56) | ALDH1A1MAPTHPGDLMNASMN1; SMN2 | |
| SCHEMBL9150174 | 0.84 | KDM4E (0.56) | ALDH1A1LMNASMN1; SMN2KDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083864-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | BAYER AG (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-4583926-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4308551-B1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AG (DE) | 2025-04-09 | — | — | EP | disclosed |
| US-20240182431-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-06 | — | — | US | disclosed |
| WO-2024052550-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| EP-4335462-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | Bayer AG (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4308551-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Aktiengesellschaft (DE) | 2024-01-24 | — | — | EP | disclosed |
| CN-114605822-B | Fullerene derivative enhanced n-type thermoelectric film and preparation method thereof | 武汉工程大学 | 2024-01-05 | — | — | CN | disclosed |
| CN-116981658-A | Novel contrast agents for magnetic resonance imaging | 拜耳股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2022194777-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-22 | — | — | WO | disclosed |
| EP-4059925-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Aktiengesellschaft (DE) | 2022-09-21 | — | — | EP | disclosed |
| CN-114605822-A | Fullerene derivative enhanced n-type thermoelectric film and preparation method thereof | 武汉工程大学 | 2022-06-10 | — | — | CN | disclosed |
| EP-0258578-B1 | LIQUID CRYSTAL COMPOUNDS HAVING ETHER TAIL MOIETY | POLAROID CORPORATION (US) | 1993-01-07 | — | — | EP | disclosed |
| US-5132041-A | Liquid crystal compounds having ether tail moiety | POLAROID CORPORATION (US) | 1992-07-21 | — | — | US | disclosed |
| EP-0258578-A2 | Liquid crystal compounds having ether tail moiety | POLAROID CORPORATION (US) | 1988-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182431-A1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | MAG, GBA1, GLRX3 | ALDH1A1 3523/4885MAPT 3428/4885HPGD 1963/4885 |
| US-20260083864-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | CA13, CCR1, GALC | ALDH1A1 1811/4885MAPT 3433/4885HPGD 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.